Ventricular assist device therapy

Gabriel Sayer, Yoshifumi Naka, Ulrich P. Jorde

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.

Original languageEnglish (US)
Pages (from-to)140-150
Number of pages11
JournalCardiovascular Therapeutics
Volume27
Issue number2
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Heart-Assist Devices
Pulsatile Flow
Therapeutics
Heart Failure
Transplantation
Morbidity
Mortality
Incidence
Research

Keywords

  • Cardiovascular physiology
  • Heart failure
  • Transplant
  • Ventricular assist devices

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Ventricular assist device therapy. / Sayer, Gabriel; Naka, Yoshifumi; Jorde, Ulrich P.

In: Cardiovascular Therapeutics, Vol. 27, No. 2, 06.2009, p. 140-150.

Research output: Contribution to journalArticle

Sayer, Gabriel ; Naka, Yoshifumi ; Jorde, Ulrich P. / Ventricular assist device therapy. In: Cardiovascular Therapeutics. 2009 ; Vol. 27, No. 2. pp. 140-150.
@article{a02b17a4066e4bcebe785809d80500c5,
title = "Ventricular assist device therapy",
abstract = "Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.",
keywords = "Cardiovascular physiology, Heart failure, Transplant, Ventricular assist devices",
author = "Gabriel Sayer and Yoshifumi Naka and Jorde, {Ulrich P.}",
year = "2009",
month = "6",
doi = "10.1111/j.1755-5922.2009.00081.x",
language = "English (US)",
volume = "27",
pages = "140--150",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Ventricular assist device therapy

AU - Sayer, Gabriel

AU - Naka, Yoshifumi

AU - Jorde, Ulrich P.

PY - 2009/6

Y1 - 2009/6

N2 - Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.

AB - Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.

KW - Cardiovascular physiology

KW - Heart failure

KW - Transplant

KW - Ventricular assist devices

UR - http://www.scopus.com/inward/record.url?scp=65549133892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549133892&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5922.2009.00081.x

DO - 10.1111/j.1755-5922.2009.00081.x

M3 - Article

C2 - 19426251

AN - SCOPUS:65549133892

VL - 27

SP - 140

EP - 150

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 2

ER -